| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Bortezomib | GDSC1000 | pan-cancer | AAC | -0.057 | 0.2 |
| mRNA | tivozanib | GDSC1000 | pan-cancer | AAC | 0.039 | 0.2 |
| mRNA | BRD-K86535717 | CTRPv2 | pan-cancer | AAC | -0.083 | 0.2 |
| mRNA | SKI-II | CTRPv2 | pan-cancer | AAC | -0.042 | 0.2 |
| mRNA | HG-6-64-1 | GDSC1000 | pan-cancer | AAC | -0.038 | 0.2 |
| mRNA | tipifarnib | CTRPv2 | pan-cancer | AAC | -0.036 | 0.2 |
| mRNA | BRD-K41334119 | CTRPv2 | pan-cancer | AAC | 0.082 | 0.2 |
| mRNA | PIK-93 | CTRPv2 | pan-cancer | AAC | -0.04 | 0.2 |
| mRNA | erlotinib:PLX-4032 (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.043 | 0.2 |
| mRNA | Doxorubicin | CTRPv2 | pan-cancer | AAC | -0.034 | 0.2 |